All In Biotech

Drug Trial Radar · NCT04247074

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

413

Actual

Start

Feb 10, 2020

Primary completion

Oct 2, 2020

Study completion Feb 26, 2021

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jan 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.

Conditions

  • Glabellar Frown Lines (GL)
  • Lateral Canthal Lines (LCL)

Interventions

  • botulinum toxin neuromodulatorBiological

    QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

  • PlaceboBiological

    Placebo will be injected into either the LCL, GL, or both the LCL and GL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum FrownTime frame: Month 1
  2. Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum SmileTime frame: Month 1

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Testing of Beverly Hills

    Encino, California

  • Ava MD

    Santa Monica, California

  • Skin Care & Laser Physicians of Beverly Hills

    West Hollywood, California

  • Center for Clinical and Cosmetic Research

    Aventura, Florida

  • Baumann Cosmetic & Research Institute, Inc

    Miami, Florida

  • Washington Institute of Dermatologic Laser Surgery

    Chevy Chase, Maryland

  • Maryland Dermatology, Laser, Skin & Vein Institute

    Hunt Valley, Maryland

  • Skin Specialists, PC

    Omaha, Nebraska

  • Lorenc Aesthetic Plastic Surgery Center

    New York, New York

  • Elite Aesthetic Research

    Cincinnati, Ohio

  • The Westlake Dermatology Clinical Research

    Austin, Texas

  • Bertucci Medspa, Inc

    Woodbridge, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.